Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of High Dose Radiotherapy in Combination With Pembrolizumab Plus Chemotherapy in Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

NCT06492759 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT06492759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06492759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of High Dose Radiotherapy in Combination With Pembrolizumab Plus Chemotherapy in Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
October 22, 2025
Completion date
February 13, 2028
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic triple-negative breast carcinoma